Chemours (CC) Stock Forecast, Price & News

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Chemours in the last year. There are currently 1 sell rating, 6 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" CC shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CC, but not buy additional shares or sell existing shares.
View CC analyst ratings or view top-rated stocks.

10 brokers have issued twelve-month price objectives for Chemours' shares. Their CC share price forecasts range from $25.00 to $64.00. On average, they anticipate the company's stock price to reach $38.78 in the next twelve months. This suggests a possible upside of 21.0% from the stock's current price.
View analysts price targets for CC or view top-rated stocks among Wall Street analysts.

Chemours' stock was trading at $30.62 at the start of the year. Since then, CC shares have increased by 4.7% and is now trading at $32.06.
View the best growth stocks for 2023 here.

Chemours saw a increase in short interest in May. As of May 15th, there was short interest totaling 4,520,000 shares, an increase of 7.4% from the April 30th total of 4,210,000 shares. Based on an average trading volume of 1,150,000 shares, the short-interest ratio is presently 3.9 days. Approximately 3.1% of the shares of the stock are short sold.
View Chemours' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, July 27th 2023.
View our CC earnings forecast.

The Chemours Company (NYSE:CC) announced its earnings results on Friday, April, 28th. The specialty chemicals company reported $0.98 earnings per share for the quarter, beating the consensus estimate of $0.62 by $0.36. The specialty chemicals company earned $1.54 billion during the quarter, compared to analyst estimates of $1.46 billion. Chemours had a net margin of 7.45% and a trailing twelve-month return on equity of 53.44%. The company's revenue for the quarter was down 12.9% on a year-over-year basis. During the same period in the previous year, the business earned $1.46 earnings per share.

Chemours announced a quarterly dividend on Thursday, April 27th. Stockholders of record on Monday, May 15th will be paid a dividend of $0.25 per share on Thursday, June 15th. This represents a $1.00 dividend on an annualized basis and a yield of 3.12%. The ex-dividend date of this dividend is Friday, May 12th.
Read our dividend analysis for CC.

ETFs with the largest weight of Chemours (NYSE:CC) stock in their portfolio include ProShares Smart Materials ETF (TINT), First Trust Materials AlphaDEX Fund (FXZ), Invesco S&P MidCap Value with Momentum ETF (XMVM), Invesco DWA Basic Materials Momentum ETF (PYZ), Invesco S&P MidCap Quality ETF (XMHQ), LeaderShares AlphaFactor US Core Equity ETF (LSAF), Pacer US Export Leaders ETF (PEXL) and Distillate Small/Mid Cash Flow ETF (DSMC).

Chemours (NYSE:CC) pays an annual dividend of $1.00 per share and currently has a dividend yield of 2.93%. The dividend payout ratio is 32.26%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, CC will have a dividend payout ratio of 20.75% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for CC.

Chemours updated its FY 2023 earnings guidance on Friday, April, 28th. The company provided earnings per share (EPS) guidance of $3.80-$4.29 for the period. The company issued revenue guidance of -.

106 employees have rated Chemours Chief Executive Officer Mark Vergnano on Glassdoor.com. Mark Vergnano has an approval rating of 85% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Chemours investors own include AT&T (T), Pfizer (PFE), DuPont de Nemours (DD), NVIDIA (NVDA), Cisco Systems (CSCO), Micron Technology (MU), Intel (INTC), AbbVie (ABBV), CVS Health (CVS) and Energy Transfer (ET).

Chemours trades on the New York Stock Exchange (NYSE) under the ticker symbol "CC."

Chemours' stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (11.83%), FMR LLC (10.23%), State Street Corp (2.98%), JPMorgan Chase & Co. (2.12%), LSV Asset Management (1.93%) and Dimensional Fund Advisors LP (1.66%). Insiders that own company stock include Alisha Bellezza, Alvenia Scarborough, David C Shelton, Denise Dignam, Edwin C Sparks, Edwin C Sparks, Mark Newman, Mark P Vergnano, Mark P Vergnano, Matthew S Abbott, Matthew S Abbott and Sameer Ralhan.
View institutional ownership trends.

Shares of CC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CC stock can currently be purchased for approximately $32.06.

Chemours (NYSE:CC) has a market capitalization of $4.78 billion and generates $6.79 billion in revenue each year. The specialty chemicals company earns $578 million in net income (profit) each year or $3.10 on an earnings per share basis.

The company employs 6,600 workers across the globe.

Chemours' mailing address is 1007 MARKET STREET, WILMINGTON DE, 19801. The official website for the company is www.chemours.com. The specialty chemicals company can be reached via phone at (302) 773-1000 or via email at investor@chemours.com.